Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanomix Corp NNMX

Healthcare Medical Devices
Nanomix Corporation is engaged in development of mobile point-of-care diagnostics. The Company operates through its Nanomix eLab System platform and assays that provide quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The platform is designed to provide rapid test results in a handheld device at the first point of patient... see more

Recent & Breaking News (OTCPK:NNMX)

Nanomix to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Business Wire March 22, 2022

Nanomix Completes 1-for-173 Reverse Stock Split

Business Wire March 2, 2022

Nanomix Announces UK MHRA Registration for New Point of Care System

Business Wire December 8, 2021

Nanomix Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19

Business Wire December 1, 2021

Boston Therapeutics Ph 2 Study Achieves Full Enrollment

GlobeNewswire August 22, 2019

Boston Therapeutics Announces Official Sales and Marketing Launch of Sugardown® in Asia

GlobeNewswire February 14, 2019

Boston Therapeutics Announces Marketing of Sugardown® in Asia

GlobeNewswire December 13, 2018

Boston Therapeutics Announces Initiation of Sales of Sugardown® in Asia

GlobeNewswire December 7, 2018

Boston Therapeutics and Prevail InfoWorks Announce Strategic Clinical Partnership

GlobeNewswire October 3, 2018

Boston Therapeutics Initiates New Exploratory and Adaptive Multicenter Clinical Study of BTI320 On Type 2 Diabetics Currently on Metformin and or Sulfonylureas in the United States

GlobeNewswire September 24, 2018

Boston Therapeutics Phase IIa Study Results Accepted for Publication

GlobeNewswire August 24, 2018

Boston Therapeutics to launch social commerce channel for Sugardown® in China

GlobeNewswire August 9, 2018

Boston Therapeutics Introduces Sugardown® to the US under kathy Ireland® Health & Wellness

GlobeNewswire June 27, 2018

Boston Therapeutics Phase I Study Results Accepted for Publication

GlobeNewswire May 10, 2018

Boston Therapeutics to Hold Business Update Conference Call Wednesday, April 18, 2018 at 5:00 p.m. ET

GlobeNewswire April 16, 2018

Boston Therapeutics Announces Letter of Intent to Acquire Pennsylvania-based Medical Technology Associates II (MTA2)

GlobeNewswire April 12, 2018

Boston Therapeutics Awarded Key European Patent

GlobeNewswire April 6, 2018

Boston Therapeutics Engages Medical and FDA Experts: Launching New Strategic Initiatives

GlobeNewswire March 29, 2018

Boston Therapeutics Creates New Scientific Advisory Board

GlobeNewswire March 27, 2018

Boston Therapeutics Joins the Biotechnology Innovation Organization (BIO)

GlobeNewswire March 8, 2018